双抗-话题@MedSci

#双抗#

81篇内容 | 3530人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1487268, encodeId=7636148e2684d, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=JACC：双抗治疗怕出血？急性冠状动脉综合征DAPT降阶梯治疗的更佳方案来了！, objectType=article, longId=215984, objectId=603a21598498, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=603a21598498, replyNumber=0, likeNumber=97, createdTime=2021-08-20, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=603a21598498, moduleTitle=JACC：双抗治疗怕出血？急性冠状动脉综合征DAPT降阶梯治疗的更佳方案来了！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=603a21598498)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487267, encodeId=730e148e26707, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=对变异毒株无效，礼来医药双抗体疗法被喊停, objectType=article, longId=213490, objectId=ba0b213490d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba0b213490d7, replyNumber=0, likeNumber=88, createdTime=2021-07-01, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba0b213490d7, moduleTitle=对变异毒株无效，礼来医药双抗体疗法被喊停, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba0b213490d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487266, encodeId=ff44148e26696, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=急性脑梗死双抗治疗首剂加倍时还是用双抗吗？, objectType=article, longId=211851, objectId=ee09211851d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee09211851d6, replyNumber=0, likeNumber=78, createdTime=2021-05-28, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee09211851d6, moduleTitle=急性脑梗死双抗治疗首剂加倍时还是用双抗吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee09211851d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487265, encodeId=3643148e265e0, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=肝癌乙肝合并急性脑梗，血小板5万，双抗吗？, objectType=article, longId=211825, objectId=22a4211825bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22a4211825bd, replyNumber=0, likeNumber=63, createdTime=2021-05-27, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22a4211825bd, moduleTitle=肝癌乙肝合并急性脑梗，血小板5万，双抗吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22a4211825bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487264, encodeId=33ea148e26453, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=辉瑞暂停BCMA/CD3双抗elranatamab的临床试验，BCMA/CD3双特异性抗体是全球研发热点, objectType=article, longId=210832, objectId=8fed21083275, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fed21083275, replyNumber=0, likeNumber=56, createdTime=2021-05-06, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fed21083275, moduleTitle=辉瑞暂停BCMA/CD3双抗elranatamab的临床试验，BCMA/CD3双特异性抗体是全球研发热点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fed21083275)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487263, encodeId=59a0148e263cd, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=Circulation | 证据来了：预防二次卒中，单抗、双抗孰优孰劣？, objectType=article, longId=210743, objectId=f3cc210e435b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3cc210e435b, replyNumber=0, likeNumber=66, createdTime=2021-05-04, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3cc210e435b, moduleTitle=Circulation | 证据来了：预防二次卒中，单抗、双抗孰优孰劣？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3cc210e435b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487262, encodeId=4299148e2627a, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=临床阶段生物制药公司宣布开展卡妥索双抗治疗非肌层浸润性膀胱癌临床I/II期试验, objectType=article, longId=209970, objectId=4f092099e063, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f092099e063, replyNumber=0, likeNumber=59, createdTime=2021-04-16, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f092099e063, moduleTitle=临床阶段生物制药公司宣布开展卡妥索双抗治疗非肌层浸润性膀胱癌临床I/II期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f092099e063)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487261, encodeId=59a4148e2618c, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=礼来的双抗体鸡尾酒疗法三期临床试验获得重要进展, objectType=article, longId=208253, objectId=ad502082536a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad502082536a, replyNumber=0, likeNumber=62, createdTime=2021-03-12, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad502082536a, moduleTitle=礼来的双抗体鸡尾酒疗法三期临床试验获得重要进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad502082536a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487260, encodeId=9b3b148e2608f, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=全球首创！康方生物PD-1/CTLA-4双抗治疗宫颈癌获美国FDA孤儿药认定, objectType=article, longId=207633, objectId=bf5620e63327, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf5620e63327, replyNumber=0, likeNumber=61, createdTime=2021-02-28, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf5620e63327, moduleTitle=全球首创！康方生物PD-1/CTLA-4双抗治疗宫颈癌获美国FDA孤儿药认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf5620e63327)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487259, encodeId=8aa3148e25929, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=罗氏2款新药在中国获批临床：CD3/CD20双抗、C5单抗, objectType=article, longId=200497, objectId=d56720049e3b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d56720049e3b, replyNumber=0, likeNumber=86, createdTime=2020-09-11, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d56720049e3b, moduleTitle=罗氏2款新药在中国获批临床：CD3/CD20双抗、C5单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d56720049e3b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487258, encodeId=a021148e258d3, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=再鼎生物CD3/CD20双抗获批5项临床，预计募资10亿美元在港二次上市, objectType=article, longId=200491, objectId=b34220049167, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b34220049167, replyNumber=0, likeNumber=65, createdTime=2020-09-11, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b34220049167, moduleTitle=再鼎生物CD3/CD20双抗获批5项临床，预计募资10亿美元在港二次上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b34220049167)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487257, encodeId=4be1148e25710, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=再鼎1.9亿美元引进再生元CD20xCD3双抗进展，已获批临床, objectType=article, longId=200450, objectId=d9ed2004503b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9ed2004503b, replyNumber=0, likeNumber=83, createdTime=2020-09-10, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9ed2004503b, moduleTitle=再鼎1.9亿美元引进再生元CD20xCD3双抗进展，已获批临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9ed2004503b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487256, encodeId=4a24148e25694, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=Regeneron的双抗体鸡尾酒疗法预防新冠病毒COVID-19感染，进入III期研究阶段, objectType=article, longId=197185, objectId=861519e185ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=861519e185ee, replyNumber=0, likeNumber=84, createdTime=2020-07-09, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=861519e185ee, moduleTitle=Regeneron的双抗体鸡尾酒疗法预防新冠病毒COVID-19感染，进入III期研究阶段, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=861519e185ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487255, encodeId=f89a148e255df, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=双抗体鸡尾酒疗法REGN-COV2：再生元启动针对新冠病毒COVID-19的首项临床研究, objectType=article, longId=195726, objectId=ad9f195e2630, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad9f195e2630, replyNumber=0, likeNumber=53, createdTime=2020-06-13, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad9f195e2630, moduleTitle=双抗体鸡尾酒疗法REGN-COV2：再生元启动针对新冠病毒COVID-19的首项临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad9f195e2630)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487254, encodeId=76de148e254c6, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=Stroke：除了降低卒中复发，双抗还能减轻残疾, objectType=article, longId=193960, objectId=4e1c193960d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e1c193960d7, replyNumber=0, likeNumber=100, createdTime=2020-05-12, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e1c193960d7, moduleTitle=Stroke：除了降低卒中复发，双抗还能减轻残疾, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e1c193960d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487253, encodeId=505d148e25377, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=AACR 2020：季加孚教授汇报PD-1/CTLA-4双抗AK104联合化疗一线治疗晚期胃或胃食管结合部癌的Ib期研究结果, objectType=article, longId=193387, objectId=c66b19338e62, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c66b19338e62, replyNumber=0, likeNumber=60, createdTime=2020-05-04, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c66b19338e62, moduleTitle=AACR 2020：季加孚教授汇报PD-1/CTLA-4双抗AK104联合化疗一线治疗晚期胃或胃食管结合部癌的Ib期研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c66b19338e62)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487252, encodeId=8544148e25204, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=建议新冠肺炎患者介入后双抗可缩至3个月！天津医大杨清等Circulation发文, objectType=article, longId=192775, objectId=9811192e757d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9811192e757d, replyNumber=0, likeNumber=64, createdTime=2020-04-24, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9811192e757d, moduleTitle=建议新冠肺炎患者介入后双抗可缩至3个月！天津医大杨清等Circulation发文, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9811192e757d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487251, encodeId=8bbd148e251f6, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=ACC 2020：PCI术后患者用3个月双抗后，单独使用替格瑞洛9个月可能更好（TICO研究）, objectType=article, longId=191563, objectId=27881915638e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27881915638e, replyNumber=0, likeNumber=69, createdTime=2020-04-08, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27881915638e, moduleTitle=ACC 2020：PCI术后患者用3个月双抗后，单独使用替格瑞洛9个月可能更好（TICO研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27881915638e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487250, encodeId=4d2f148e25083, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=Neurology：静脉溶栓前双抗预治疗的结局, objectType=article, longId=190786, objectId=41cf190e8687, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41cf190e8687, replyNumber=0, likeNumber=83, createdTime=2020-03-26, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41cf190e8687, moduleTitle=Neurology：静脉溶栓前双抗预治疗的结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41cf190e8687)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487249, encodeId=2497148e24939, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, objectTitle=Stroke：肥胖患者还能服用双抗吗？, objectType=article, longId=188825, objectId=2ca0188825fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ca0188825fb, replyNumber=0, likeNumber=79, createdTime=2020-02-27, rootId=0, userName=yeye5224615, userId=bbaa8296156, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ca0188825fb, moduleTitle=Stroke：肥胖患者还能服用双抗吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ca0188825fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

双抗

2020-05-29

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

JACC：双抗治疗怕出血？急性冠状动脉综合征DAPT降阶梯治疗的更佳方案来了！

2021-08-20

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

对变异毒株无效，礼来医药双抗体疗法被喊停

2021-07-01

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

急性脑梗死双抗治疗首剂加倍时还是用双抗吗？

2021-05-28

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

肝癌乙肝合并急性脑梗，血小板5万，双抗吗？

2021-05-27

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

辉瑞暂停BCMA/CD3双抗elranatamab的临床试验，BCMA/CD3双特异性抗体是全球研发热点

2021-05-06

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

Circulation | 证据来了：预防二次卒中，单抗、双抗孰优孰劣？

2021-05-04

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

临床阶段生物制药公司宣布开展卡妥索双抗治疗非肌层浸润性膀胱癌临床I/II期试验

2021-04-16

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

礼来的双抗体鸡尾酒疗法三期临床试验获得重要进展

2021-03-12

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

全球首创！康方生物PD-1/CTLA-4双抗治疗宫颈癌获美国FDA孤儿药认定

2021-02-28

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

罗氏2款新药在中国获批临床：CD3/CD20双抗、C5单抗

2020-09-11

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

再鼎生物CD3/CD20双抗获批5项临床，预计募资10亿美元在港二次上市

2020-09-11

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

再鼎1.9亿美元引进再生元CD20xCD3双抗进展，已获批临床

2020-09-10

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

Regeneron的双抗体鸡尾酒疗法预防新冠病毒COVID-19感染，进入III期研究阶段

2020-07-09

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

双抗体鸡尾酒疗法REGN-COV2：再生元启动针对新冠病毒COVID-19的首项临床研究

2020-06-13

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

Stroke：除了降低卒中复发，双抗还能减轻残疾

2020-05-12

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

AACR 2020：季加孚教授汇报PD-1/CTLA-4双抗AK104联合化疗一线治疗晚期胃或胃食管结合部癌的Ib期研究结果

2020-05-04

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

建议新冠肺炎患者介入后双抗可缩至3个月！天津医大杨清等Circulation发文

2020-04-24

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

ACC 2020：PCI术后患者用3个月双抗后，单独使用替格瑞洛9个月可能更好（TICO研究）

2020-04-08

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

Neurology：静脉溶栓前双抗预治疗的结局

2020-03-26

yeye5224615 (审核中...)

前往app查看评论内容

#双抗#

Stroke：肥胖患者还能服用双抗吗？

2020-02-27

科室
- - 订阅+
  - 更多科室
工具
服务